Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 May;35(5):e21573.
doi: 10.1096/fj.202100280RR.

Potential 3-chymotrypsin-like cysteine protease cleavage sites in the coronavirus polyproteins pp1a and pp1ab and their possible relevance to COVID-19 vaccine and drug development

Shaomin Yan  1 , Guang Wu  1
Affiliations
Review

Potential 3-chymotrypsin-like cysteine protease cleavage sites in the coronavirus polyproteins pp1a and pp1ab and their possible relevance to COVID-19 vaccine and drug development

Shaomin Yan et al. FASEB J. 2021 May.

Abstract

Coronavirus (CoV) 3-chymotrypsin (C)-like cysteine protease (3CLpro ) is a target for anti-CoV drug development and drug repurposing because along with papain-like protease, it cleaves CoV-encoded polyproteins (pp1a and pp1ab) into nonstructural proteins (nsps) for viral replication. However, the cleavage sites of 3CLpro and their relevant nsps remain unclear, which is the subject of this perspective. Here, we address the subject from three standpoints. First, we explore the inconsistency in the cleavage sites and relevant nsps across CoVs, and investigate the function of nsp11. Second, we consider the nsp16 mRNA overlapping of the spike protein mRNA, and analyze the effect of this overlapping on mRNA vaccines. Finally, we study nsp12, whose existence depends on ribosomal frameshifting, and investigate whether 3CLpro requires a large number of inhibitors to achieve full inhibition. This perspective helps us to clarify viral replication and is useful for developing anti-CoV drugs with 3CLpro as a target in the current coronavirus disease 2019 (COVID-19) pandemic.

Keywords: 3CLpro; COVID-19; MERS-CoV; SARS-CoV; SARS-CoV-2; nsp.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Yang H, Yang M, Ding Y, et al. The crystal structures of severe acute respiratory syndrome virus main protease and its complex with an inhibitor. Proc Natl Acad Sci USA. 2003;100:13190‐13195. - PMC - PubMed
    1. Yang H, Xie W, Xue X, et al. Design of wide‐spectrum inhibitors targeting coronavirus main proteases. PLoS Biol. 2005;3:e324. - PMC - PubMed
    1. Zhang S, Zhong N, Xue F, et al. Three‐dimensional domain swapping as a mechanism to lock the active conformation in a super‐active octamer of SARS‐CoV main protease. Protein Cell. 2010;1:371‐383. - PMC - PubMed
    1. Abuhammad A, Al‐Aqtash RA, Anson BJ, Mesecar AD, Taha MO. Computational modeling of the Bat HKU4 coronavirus 3CL(pro) inhibitors as a tool for the development of antivirals against the emerging Middle East Respiratory Syndrome (MERS) coronavirus. J Mol Recognit. 2017;30:e2644. - PMC - PubMed
    1. Galasiti Kankanamalage AC, Kim Y, Damalanka VC, et al. Structure‐guided design of potent and permeable inhibitors of MERS coronavirus 3CL protease that utilize a piperidine moiety as a novel design element. Eur J Med Chem. 2018;150:334‐346. - PMC - PubMed

Publication types

MeSH terms

LinkOut - more resources